Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Factor VII Activity (1:40)

Coagulation

F7 activityFactor VII 1:40FVIIProconvertin activity

Review status

Currently under review

Pending specialist review and validation.

What it shows

The Factor VII activity test checks how well factor VII, a clotting protein made in the liver and dependent on vitamin K, is working in your blood. It is a functional assay that measures the ability of this factor to help start the clotting process in a controlled laboratory reaction.

Your plasma is combined with specific reagents to trigger clotting, and the laboratory calculates the activity of factor VII from the response. The term 1:40 refers to a dilution used during the procedure; it is part of the method and does not reflect your personal result.

Why it matters

This test helps find the cause of unusual bruising or bleeding, especially when your prothrombin time (PT) is prolonged. It can identify inherited factor VII deficiency, reveal vitamin K deficiency, show effects of certain medicines, and provide clues about liver function. It is also used to plan safely for surgery or dental work and to monitor treatment if you receive factor replacement.

Results are interpreted with other coagulation tests, such as PT/INR and panels of clotting factors, to give a clearer picture of your clotting system. Knowing your factor VII activity can guide decisions about treatment, timing of procedures, and whether additional testing is needed.

Understanding your results

A lower-than-expected factor VII activity can be due to an inherited deficiency, vitamin K deficiency, liver problems, or the intended effect of vitamin K–blocking medicines. Some antibiotics, poor nutrition, or gut absorption issues can also reduce vitamin K and lower activity. Higher-than-expected activity is less common but can occur with inflammation, estrogen-containing therapies, or during pregnancy.

Your care team will look at your symptoms, medication list, diet, and other lab results to interpret what the number means for you. If findings are unexpected, follow-up may include repeating the test with careful sample handling, checking PT/INR, measuring other factors, or performing a mixing study to tell a true deficiency from an inhibitor. In select cases, genetic testing or evaluation of liver and vitamin K status may be considered.

Reference ranges

0.51.5 U/mL
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Factor VII Activity (1:40)

  • Vitamin K status and diet

    Low vitamin K intake, malabsorption, or bowel disease can lower factor VII activity. Vitamin K supplements can raise activity, so tell your clinician what you take.

  • Medications

    Vitamin K antagonists such as warfarin lower factor VII. Some antibiotics and certain herbal products can also affect vitamin K metabolism and your result.

  • Liver health

    Factor VII is made in the liver. Liver inflammation or scarring can reduce production, leading to lower measured activity on testing.

  • Pregnancy and estrogen therapy

    Pregnancy and estrogen-containing therapies may increase factor VII activity. Your clinician will interpret results in this context.

  • Sample collection and handling

    Improper tube fill, prolonged tourniquet time, delayed processing, or very high hematocrit can artifactually alter clot-based results.

  • Acute illness and inflammation

    Acute phase reactions, infection, or stress can transiently change coagulation factor levels, including factor VII.

2026

References

  1. McGill University Health Centre. (2015, March 01). Factor VII 1:40 (Task CD 701497). Laboratory reference ranges.
  2. Clinical and Laboratory Standards Institute. (2008). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays; Approved guideline (CLSI document H21-A5).
  3. Clinical and Laboratory Standards Institute. (2014). One-stage prothrombin time (PT) test; Approved guideline (CLSI document H47-A2).
  4. British Society for Haematology. (2014). Guideline on the laboratory investigation of heritable disorders of haemostasis.